. Author manuscript; available in PMC: 2014 Apr 1.

Published in final edited form as: Ther Drug Monit. 2013 Apr;35(2):209–216. doi: 10.1097/FTD.0b013e318280d0ad

Table 2.

Associations between targeted polymorphisms and week 2 plasma trough protease inhibitor concentrations.

Polymorphism (Drug)	Genotype	White			Black			Hispanic			Linear Regression ^a
Polymorphism (Drug)	Genotype	n	median Level (ln ng/mL)	P-value^b	n	Median Level (ln ng/mL)	P-value^b	n	Median Level (ln ng/mL)	P-value^b	Geometric mean ratio ^c	95% confidence interval	P-value
SLCO1B1
rs4149056
lopinavir	CC	2	9.15	0.01	0	n/a	0.19	0	n/a	0.1	1.38	[0.77, 1.15]	0.07
	CT	16	8.85		1	9.28		1	9.56
	TT	32	8.54		30	8.69		16	8.66
fos-amprenavir	CC	0	n/a	0.03	0	n/a	0.59	0	n/a	0.1	0.65	[0.44, 0.94]	0.02
	CT	7	7.26		1	7.73		3	7.15
	TT	30	7.65		16	7.61		12	7.70
saquinavir	CC	0	n/a	0.98	0	n/a	0.88	0	n/a	0.61	1.25	[0.77, 2.03]	0.37
	CT	13	6.29		1	6.46		5	6.42
	TT	35	6.46		24	5.99		21	6.44
CYP3A5
rs776746
lopinavir	AA	0	n/a	0.03	18	8.78	0.45	2	8.65	0.9	0.94	[0.77, 1.15]	0.53
	AG	9	8.40		12	8.56		6	8.53
	GG	43	8.84		1	8.88		10	8.66
fos-amprenavir	AA	1	8.15	0.23	10	7.61	0.61	0	n/a	0.46	0.99	[0.82, 1.21]	0.96
	AG	3	7.02		5	7.46		7	7.62
	GG	34	7.65		2	7.72		8	7.64
saquinavir	AA	0	n/a	0.87	0	n/a	0.91	0	n/a	0.38	1.25	[0.70, 1.15]	0.37
	AG	13	6.29		1	6.46		5	6.42
	GG	35	6.46		24	5.99		21	6.44

Parameter estimates represent mean fold change ratios in week 2 trough concentration per allele variant.

Nominal P values for Jonckheere-Terpstra trend test.

Adjusted for additional PI other than ritonavir, and for race/ethnicity and concomitant PIs.